Does Semax help with anxiety?
Yes, in animal studies. Semax has a documented anxiolytic effect—reducing anxiety. However, the evidence is purely preclinical. And the effect strongly depends on the animal's baseline emotional state. It does not appear uniformly under all conditions. This point is very important. In one study, researchers analyzed normal, unstressed conditions. Semax did not change the animals' emotional state at all. There was no measurable effect on anxiety when anxiety was not already elevated [1]. However, researchers tested a different scenario. They used cholecystokinin-tetrapeptide (CCK-4) to artificially induce anxiety. This compound reliably causes anxiety and panic-like reactions. Under these conditions, Semax normalized the disturbed behavior. It showed a clear anxiolytic and antidepressant effect—but only when anxiety was already elevated [1].
The same pattern also appears in studies of chronic administration. No baseline effect. Significant effect with elevated anxiety. When Semax was administered daily for one to two weeks to normal rats, it induced measurable anxiolytic and antidepressant effects. It did not significantly alter exploratory activity in a non-stressful environment [2]. Researchers proposed a mechanism. They suggested that the effect worked by activating the brain's serotonin system. Increased BDNF production in the hippocampus likely also played a role [2].
What happens to anxiety specifically under conditions of chronic stress?
The strongest evidence for Semax's anxiolytic properties comes from chronic stress models. In these studies, the peptide reversed several markers of prolonged stress exposure.
One study used a chronic unpredictable stress protocol. This is a standard way to simulate prolonged psychological stress in animals. Semax reversed several things. It reversed stress-induced anhedonia—the loss of the ability to feel pleasure. This is closely linked to both anxiety and depression. Semax also prevented stress-related suppression of weight gain. It reduced adrenal gland enlargement, a marker of chronic overactivation of stress hormones. And it restored BDNF levels in the hippocampus that stress had reduced [3]. A separate study confirmed similar effects using the same stress model [4].
Another study analyzed the genetic response to acute stress. Researchers administered Semax 30 minutes before a stressful immobilization procedure. It significantly reduced stress-induced behavioral changes in rats. Over 1500 genes in the hippocampus changed their activity pattern as a result [5]. This correction reversed the disruptions caused by stress itself. This tells us something important. The anxiety-reducing effect is not just a behavioral change. It is linked to a genuine molecular correction at the gene level.
How does Semax affect anxiety at the brain level?
Semax appears to reduce stress-related activation in brain regions involved in fear and threat processing.
Researchers analyzed rats with different natural predispositions to emotional stress. Semax injection reduced stress-induced c-Fos gene activation. This gene is a marker of recent neuronal activity. The reduction occurred specifically in the paraventricular nucleus of the hypothalamus and the medial septum. Both areas are central to the stress response. This effect was observed in animals naturally predisposed to anxiety [6]. Semax also reduced stress-induced c-Fos activity in the lateral septum and the basolateral amygdala. The amygdala is the main center for fear and threat detection in the brain [6]. This pattern offers a credible biological explanation. It helps explain the anxiety-reducing behavioral effects seen elsewhere.
Functional connectivity research added human evidence. Researchers analyzed healthy human volunteers using brain imaging. They examined how Semax affected communication between the amygdala and other brain regions. They found measurable changes in amygdala-related connectivity after Semax administration [7]. This study did not use a formal measure of anxiety symptoms. However, it supports the idea that Semax impacts anxiety-related brain circuits in humans.
How quickly does Semax help with anxiety?
Chronic administration studies revealed something specific. Anxiolytic effects developed over one to two weeks of daily dosing [2]. They did not appear immediately after a single dose. This suggests that Semax's anti-anxiety benefits build up gradually. They do not act as an immediate tranquilizer. This fits with the underlying mechanism. Serotonin activity and BDNF production change gradually. These are processes that unfold over days to weeks, not instantaneously.
Is there human evidence for Semax and anxiety?
Direct human evidence is limited. A functional connectivity brain imaging study involved 52 healthy participants. It showed that Semax affects brain connectivity associated with the amygdala [7]. This is useful background information. However, the study did not measure clinical anxiety symptoms. It also did not use validated anxiety questionnaires.
No published clinical trials have tested Semax as a treatment for diagnosed anxiety disorders in humans. The evidence is mechanistically encouraging. But for anxiety specifically, it remains heavily in the animal study phase.
Does Semax help with depression?
Semax exhibits antidepressant-like effects in animal models of depression. The most convincing evidence comes from the chronic unpredictable stress study. This is one of the standard, well-validated ways of modeling depression-like states in animals.
In this study, chronic low-dose Semax treatment reversed several key features of a depression-like state. These features were induced by prolonged unpredictable stress in male rats. Semax reversed anhedonia—as measured by reduced preference for sugar water solution. It reversed body weight suppression. It reversed adrenal gland enlargement. And it reversed reduced hippocampal BDNF levels [3]. Reduced hippocampal BDNF is one of the most consistently replicated findings in depression research across species. Semax's ability to restore it here is therefore significant.
Researchers also compared Semax with Melanotan II in the same study. Melanotan II is a stronger activator of the same melanocortin receptor pathway. Both compounds induced similar antidepressant effects at low doses [3]. This suggests that the antidepressant effect may occur through melanocortin receptors common to both compounds. However, neither compound affected the duration of immobility in the forced swim test. This is another standard measure in antidepressant research. Therefore, the antidepressant profile was not uniform across all tests [3].
Does Semax work as an antidepressant clinically?
A direct scientific comment on this topic appeared. The 2008 comment, titled „Therapeutic Possibility of Using 'Semax’ in Depression,” posed exactly this question in psychiatric literature [8]. It reflects genuine scientific interest in Semax's antidepressant potential.
However, this was only commentary. It discussed the possibility and rationale, not actual patient data. No controlled clinical trials have tested Semax as a treatment for clinical depression. This remains true to this day.
How does Semax affect mood more broadly?
A study of chronic administration in unstressed rats revealed something noteworthy. Semax induced measurable antidepressant effects even without an imposed depression model. It simultaneously also induced anxiolytic effects. Researchers attributed both to two things: activation of serotonergic brain systems and increased production of BDNF in the hippocampus [2].
The known effects of Semax on serotonin are also relevant here. It increases serotonin turnover in the striatum. This is supported by elevated levels of 5-HIAA, a metabolite of serotonin, which persist for several hours after administration [9]. Increased serotonergic activity is a common target of most conventional antidepressants. Semax achieves this effect through a completely different pharmacological pathway than SSRIs, but the endpoint overlaps.
A related study offers an interesting angle. Young rats were exposed early in life to the SSRI antidepressant fluvoxamine. This disrupted their later anxiety-like behavior, learning abilities, and biogenic amine levels. Subsequent treatment with Semax reduced the resulting anxiety-like behavior. It improved learning. And it normalized the disrupted levels of brain chemicals [10]. This suggests that Semax may help correct mood and behavioral disorders resulting from early-life serotonin system disruptions—even in a developmental context very different from adult depression.
Is Semax or Selank better for depression?
Direct comparative data are limited. No peptide has been tested directly in a depression-focused study. However, their mechanisms differ significantly.
The antidepressant effects of Semax appear to be linked to serotonin activation and increased BDNF [2], [3]. These mechanisms closely resemble how conventional antidepressants work. Selank's main documented mechanism is different. It is anxiolytic, acting by modulating GABA and reducing stress-induced pro-inflammatory signaling proteins [11]. This profile aligns more directly with reducing anxiety and stress than with depression-specific mechanisms.
Based on available evidence, Semax has a slightly stronger theoretical rationale for depression-related symptoms. Selank's strength lies more clearly in the reduction of anxiety and stress. However, this remains a conclusion from separate studies — not a direct comparison.
Which is better for anxiety, Semax or Selank?
Selank has a more direct and consistent anxiolytic profile. Semax's anti-anxiety effects are more conditional. They appear clearly under stress or elevated anxiety. But not necessarily at baseline. This distinction is important.
Semax studies show a clear pattern. It normalized anxiety specifically when anxiety was artificially elevated - by CCK-4 or by chronic stress. Under non-stressed, normal conditions, it did not cause a measurable effect in at least one study [1]. Selank works differently. It is fundamentally built around an anxiolytic mechanism. Its documented action includes modulation of GABA receptors. It also inhibits enzymes that break down enkephalins, prolonging the activity of the brain's own natural calming opioid-like peptides [11], [12]. These mechanisms are at the core of anxiety reduction. They are not a secondary effect that appears only under specific conditions.
How do Semax and Selank compare mechanistically in the context of anxiety?
Semax's effects on anxiety appear to be downstream consequences of broader actions. These include serotonergic activation, increased BDNF, and suppressed stress-related brain activation in the amygdala and hypothalamus [1], [2], [6]. It is not a dedicated anxiolytic mechanism—it is a byproduct of other systems.
Selank's anxiolytic action is more direct. It works via the GABA system, the brain's primary calming neurotransmitter pathway. It also works by inhibiting enkephalinase, prolonging the natural calming effects of the brain's own opioid-like peptides [11].
Both peptides inhibit the same enzymes that break down enkephalins in human serum. Semax has an IC50 of 10 micromoles. Selank has an IC50 of 20 micromoles [12]. The IC50 measures the concentration required to achieve 50% inhibition. This means that Semax is actually more potent in this specific mechanism. This is the case even though Selank is the peptide more commonly associated with reducing anxiety in general. This is an interesting detail. It shows that their mechanisms truly overlap rather than being completely distinct.
Which is more calming - Semax or Selank?
Selank is generally considered to be more directly sedating of the two peptides. This reflects its pharmacological design and primary research focus. Semax is better characterized otherwise. It is activating and cognitively stimulating. Its anxiolytic effects manifest more clearly under stress. It does not function as a general sedative.
This distinction aligns with how the two peptides are typically discussed in Russian pharmacological literature. Semax is a nootropic. Selank is an anxiolytic. Both were developed by the same research group. Both use the same core glyproline peptide technology. And they share some overlapping mechanisms [13].
Can the combination of Semax and Selank help with anxiety?
Functional connectivity research analyzed both peptides in the same 52 healthy participants. Semax and Selank induced both common and distinct effects. These effects appeared on the functional connectivity between the amygdala and temporal cortex areas [7]. The researchers noted something important. This allowed them, for the first time, to define both general and peptide-specific effects on this brain connection [7].
This discovery suggests something theoretically useful. Coupling two peptides could address a broader range of anxiety-related neural circuits than either compound alone. They seem to engage at least partially distinct neural pathways. They also share some common ground. However, there is one limitation. The study did not test the peptides when administered together as a combination. It only tested them separately within the same pool of participants. This therefore remains an inference, not direct proof of combined efficacy.
What is better specifically for social anxiety?
No study has directly tested any of the peptides for social anxiety. Neither in an animal model nor in a clinical setting.
Considering the more directly anxiolytic, GABA-modulating mechanism of Selank [11], it would theoretically be a more appropriate choice. Social anxiety centers on the fear of social appraisal and judgment. The stimulating, dopamine-enhancing properties of Semax [9] could theoretically work against this. If these properties increase general arousal or vigilance, they might exacerbate, rather than reduce, social fears. This is speculative reasoning, however. Neither peptide has been studied in this specific context.
What are users reporting about anxiety - Semax or Selank?
User reports exist mainly in online nootropic communities. They cannot be verified or systematically evaluated like data from clinical trials.
These reports generally reflect the mechanistic pattern described above. Selank is more often described as sedating. Semax is more often described as activating—sometimes even mildly anxiogenic in sensitive individuals at higher doses. This fits with its dopaminergic and stimulating properties. These anecdotal patterns align reasonably well with what pharmacological studies would predict. This lends them a degree of credibility. However, they remain unverified individual reports. They should be weighted accordingly.
Disclaimer
This content is for educational and informational-scientific purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. It should not be treated as a suggestion to replace established treatments for anxiety or depression. Semax and Selank remain research compounds in most countries, including the United States and most European countries. Neither is approved by the FDA or EMA for any medical condition, including anxiety or depressive disorders. Both are approved and clinically used in Russia and some Eastern European countries for other indications. No controlled clinical trials have evaluated either compound as a treatment for diagnosed anxiety or clinical depression in humans. Most of the evidence comes from preclinical animal studies and a very limited number of human studies examining brain connectivity rather than clinical symptoms. Anyone experiencing symptoms of anxiety or depression should speak with a qualified healthcare professional or mental health specialist. Do not change, discontinue, or substitute any prescribed treatment without medical guidance. If you are experiencing thoughts of self-harm or are in emotional distress, please contact a mental health professional or a crisis support line in your area.
References
[1] Levitskaia, N. G., Vilenskiĭ, D. A., Sebentsova, E. A., Anreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action. News of the Academy of Sciences, Biological Series, (2), 231–237. PMID: 20387390
[2] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024
[3] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
Heptapeptide Semax attenuates the effects of chronic unpredictable stress in rats. Doklady Biological Sciences, 453, 353–357. https://doi.org/10.1134/S0012496613060161
Filippenkov, I. B., Stavchansky, V. V., Glazova, N. Yu., Sebentsova, E. A., Remizova, J. A., Valieva, L. V., Levitskaya, N. G., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Antistress action of melanocortin derivatives associated with correction of gene expression patterns in the hippocampus of male rats following acute stress. International Journal of Molecular Sciences, 22(18), 10054. https://doi.org/10.3390/ijms221810054
[6] Umriukhin, P. E., Koplik, E. V., Grivennikov, I. A., Miasoedov, N. F., & Sudakov, K. V. (2001). Gene c-Fos expression in the brain of rats resistant and predisposed to emotional stress after intraperitoneal injection of the ACTH(4-10) analog — Semax. Journal of Higher Nervous Activity named after I. P. Pavlov, 51(2), 220–227. PMID: 11548604
[7] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
Pae, C. U. (2008). Therapeutic possibility of „Semax” for depression. CNS Spectrums, 13(1), 20–21. https://doi.org/10.1017/s1092852900016102
[9] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[10] Glazova, N. Yu., Manchenko, D. M., Volodina, M. A., Merchieva, S. A., Andreeva, L. A., Kudrin, V. S., Myasoedov, N. F., & Levitskaya, N. G. (2021). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
[11] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810
[12] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
Ashmarin, I. P., Samonina, G. E., Lyapina, L. A., Kamenskii, A. A., Levitskaya, N. G., Grivennikov, I. A., Dolotov, O. V., Andreeva, L. A., & Myasoedov, N. F. (2005). Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001